Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick R Verhoest

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for SchizophreniaAmy B Dounay, Marie Anderson, Bruce M Bechle, et al.
Journal of Medicinal Chemistry|January 3, 2018
Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical CandidateChristopher J Helal, Eric Arnold, Tracey Boyden, et al.
Journal of Medicinal Chemistry|January 8, 2014
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulatorLei Zhang, Gayatri Balan, Gabriela Barreiro, et al.
Journal of Medicinal Chemistry|June 7, 2024
Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's DiseaseMartin Pettersson, Douglas S Johnson, John M Humphrey, et al.
Journal of Medicinal Chemistry|August 18, 2017
Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman PrimatesAntonia F Stepan, Michelle M Claffey, Matthew R Reese, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for SchizophreniaAmy B Dounay, Marie Anderson, Bruce M Bechle, et al.
Journal of Medicinal Chemistry|January 3, 2018
Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical CandidateChristopher J Helal, Eric Arnold, Tracey Boyden, et al.
Journal of Medicinal Chemistry|January 8, 2014
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulatorLei Zhang, Gayatri Balan, Gabriela Barreiro, et al.
Journal of Medicinal Chemistry|June 7, 2024
Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's DiseaseMartin Pettersson, Douglas S Johnson, John M Humphrey, et al.
Journal of Medicinal Chemistry|August 18, 2017
Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman PrimatesAntonia F Stepan, Michelle M Claffey, Matthew R Reese, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 4